Analysts expect that argenx SE – (NASDAQ:ARGX) will post ($1.14) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for argenx’s earnings, with estimates ranging from ($1.60) to ($0.73). The company is scheduled to issue its next earnings results on Thursday, October 24th.
On average, analysts expect that argenx will report full year earnings of ($3.41) per share for the current financial year, with EPS estimates ranging from ($3.66) to ($2.88). For the next financial year, analysts expect that the business will report earnings of ($7.05) per share, with EPS estimates ranging from ($10.00) to ($4.84). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow argenx.
Several analysts recently issued reports on ARGX shares. SunTrust Banks raised their target price on argenx from $150.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday. Stifel Nicolaus reissued a “buy” rating and issued a $154.00 target price on shares of argenx in a research note on Thursday, August 1st. Piper Jaffray Companies reissued an “overweight” rating on shares of argenx in a research note on Friday, November 8th. ValuEngine cut argenx from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Zacks Investment Research raised argenx from a “sell” rating to a “hold” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. argenx has a consensus rating of “Buy” and a consensus price target of $158.50.
Institutional investors have recently bought and sold shares of the business. Bank of Montreal Can boosted its position in argenx by 62.7% during the 2nd quarter. Bank of Montreal Can now owns 58,441 shares of the company’s stock valued at $8,274,000 after acquiring an additional 22,520 shares in the last quarter. Meadow Creek Investment Management LLC bought a new stake in argenx during the 2nd quarter valued at approximately $215,000. Vestmark Advisory Solutions Inc. boosted its position in argenx by 8.2% during the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 2,281 shares of the company’s stock valued at $260,000 after acquiring an additional 172 shares in the last quarter. Royal Bank of Canada boosted its position in argenx by 44.5% during the 2nd quarter. Royal Bank of Canada now owns 3,009 shares of the company’s stock valued at $426,000 after acquiring an additional 926 shares in the last quarter. Finally, Artal Group S.A. boosted its position in argenx by 10.0% during the 2nd quarter. Artal Group S.A. now owns 220,000 shares of the company’s stock valued at $31,148,000 after acquiring an additional 20,000 shares in the last quarter. 58.47% of the stock is currently owned by institutional investors and hedge funds.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Hang Seng Index (HSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.